Search Results - "Noel Barrett, P."

Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases by Barrett, P Noel, Terpening, Sara J, Snow, Doris, Cobb, Ronald R, Kistner, Otfried

“…Rapid development and production of vaccines against emerging diseases requires well established, validated, robust technologies to allow industrial scale…”
Get full text

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects by Scherrer, Didier, Rouzier, Regine, Noel Barrett, P, Steens, Jean-Marc, Gineste, Paul, Murphy, Robert L, Tazi, Jamal, Ehrlich, Hartmut J

“…An anti-HIV compound (ABX464) has been developed with a novel mechanism of activity in that it blocks viral gene expression in cells that are already infected…”
Get full text

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses by Hessel, Annett, Savidis-Dacho, Helga, Coulibaly, Sogue, Portsmouth, Daniel, Kreil, Thomas R, Crowe, Brian A, Schwendinger, Michael G, Pilz, Andreas, Barrett, P Noel, Falkner, Falko G, Schäfer, Birgit

“…The availability of a universal influenza vaccine able to induce broad cross-reactive immune responses against diverse influenza viruses would provide an…”
Get full text

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture by Ehrlich, Hartmut J, Müller, Markus, Oh, Helen M.L, Tambyah, Paul A, Joukhadar, Christian, Montomoli, Emanuele, Fisher, Dale, Berezuk, Greg, Fritsch, Sandor, Löw-Baselli, Alexandra, Vartian, Nina, Bobrovsky, Roman, Pavlova, Borislava G, Pöllabauer, Eva Maria, Kistner, Otfried, Barrett, P. Noel

“…There is a need for a vaccine against avian influenza (H5N1). In this initial study, the administration of two doses of a whole-virus H5N1 vaccine derived from…”
Get full text

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial by Barrett, P Noel, Dr, Berezuk, Gregory, MS, Fritsch, Sandor, PhD, Aichinger, Gerald, MD, Hart, Mary Kate, PhD, El-Amin, Wael, MD, Kistner, Otfried, PhD, Ehrlich, Hartmut J, MD

“…Summary Background The use of cell-culture technologies for the manufacture of influenza vaccines might contribute to improved strain selection and robust…”
Get full text

A Tick-borne Encephalitis Virus Vaccine Based on the European Prototype Strain Induces Broadly Reactive Cross-neutralizing Antibodies in Humans by Orlinger, Klaus K., Hofmeister, Yvonne, Fritz, Richard, Holzer, Georg W., Falkner, Falko G., Unger, Bernd, Loew-Baselli, Alexandra, Poellabauer, Eva-Maria, Ehrlich, Hartmut J., Barrett, P. Noel, Kreil, Thomas R.

“…After vaccination of humans with tick-borne encephalitis virus (TBEV) vaccine, the extent of crossneutralization between viruses of the European, Far Eastern,…”
Get full text

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial by Wressnigg, Nina, PhD, Pöllabauer, Eva-Maria, MD, Aichinger, Gerald, MD, Portsmouth, Daniel, PhD, Löw-Baselli, Alexandra, PhD, Fritsch, Sandor, PhD, Livey, Ian, PhD, Crowe, Brian A, PhD, Schwendinger, Michael, PhD, Brühl, Peter, PhD, Pilz, Andreas, PhD, Dvorak, Thomas, PhD, Singer, Julia, PhD, Firth, Clair, MSc, Luft, Benjamin, Prof, Schmitt, Bernhard, MD, Zeitlinger, Markus, MD, Müller, Markus, Prof, Kollaritsch, Herwig, Prof, Paulke-Korinek, Maria, MD, Esen, Meral, MD, Kremsner, Peter G, Prof, Ehrlich, Hartmut J, MD, Barrett, P Noel, Dr

“…Summary Background Lyme borreliosis is caused by Borrelia burgdorferi sensu stricto in the USA and by several Borrelia species in Europe and Asia, but no human…”
Get full text

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato by Wressnigg, Nina, Barrett, P Noel, Pöllabauer, Eva-Maria, O'Rourke, Maria, Portsmouth, Daniel, Schwendinger, Michael G, Crowe, Brian A, Livey, Ian, Dvorak, Thomas, Schmitt, Bernhard, Zeitlinger, Markus, Kollaritsch, Herwig, Esen, Meral, Kremsner, Peter G, Jelinek, Tomas, Aschoff, Roland, Weisser, Roland, Naudts, Ingomar F K, Aichinger, Gerald

“…Lyme borreliosis (LB) patients who recover, as well as previously infected asymptomatic individuals, remain vulnerable to reinfection with Borrelia burgdorferi…”
Get full text

Quantitative detection of Borrelia burgdorferi sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR by O'Rourke, Maria, Traweger, Andreas, Lusa, Lara, Stupica, Dasa, Maraspin, Vera, Barrett, P Noel, Strle, Franc, Livey, Ian

“…B. burgdorferi sensu stricto, B. afzelii, B. garinii and B. bavariensis are the principal species which account for Lyme borreliosis (LB) globally. We have…”
Get full text

Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs by Wodal, Walter, Schwendinger, Michael G, Savidis-Dacho, Helga, Crowe, Brian A, Hohenadl, Christine, Fritz, Richard, Brühl, Peter, Portsmouth, Daniel, Karner-Pichl, Anita, Balta, Dalida, Grillberger, Leopold, Kistner, Otfried, Barrett, P Noel, Howard, M Keith

“…A novel avian H7N9 virus with a high case fatality rate in humans emerged in China in 2013. We evaluated the immunogenicity and protective efficacy of a…”
Get full text

An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial by Wressnigg, Nina, van der Velden, Maikel V W, Portsmouth, Daniel, Draxler, Wolfgang, O'Rourke, Maria, Richmond, Peter, Hall, Stephen, McBride, William J H, Redfern, Andrew, Aaskov, John, Barrett, P Noel, Aichinger, Gerald

“…Ross River virus (RRV) is endemic in Australia and several South Pacific Islands. More than 90,000 cases of RRV disease, which is characterized by debilitating…”
Get full text

Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes by Fritz, Richard, Orlinger, Klaus K, Hofmeister, Yvonne, Janecki, Kathrin, Traweger, Andreas, Perez-Burgos, Laura, Barrett, P. Noel, Kreil, Thomas R

“…Highlights ► Use of an unbiased test system for quantitative comparison of TBE vaccines. ► Efficacy against TBE viruses of Far Eastern and European suptypes…”
Get full text

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models by Kistner, Otfried, Crowe, Brian A, Wodal, Walter, Kerschbaum, Astrid, Savidis-Dacho, Helga, Sabarth, Nicolas, Falkner, Falko G, Mayerhofer, Ines, Mundt, Wolfgang, Reiter, Manfred, Grillberger, Leopold, Tauer, Christa, Graninger, Michael, Sachslehner, Alois, Schwendinger, Michael, Brühl, Peter, Kreil, Thomas R, Ehrlich, Hartmut J, Barrett, P Noel

“…The recent emergence and rapid spread of a novel swine-derived H1N1 influenza virus has resulted in the first influenza pandemic of this century. Monovalent…”
Get full text

Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection by Holzer, Georg W, Coulibaly, Sogue, Aichinger, Gerald, Savidis-Dacho, Helga, Mayrhofer, Josef, Brunner, Susanne, Schmid, Karl, Kistner, Otfried, Aaskov, John G, Falkner, Falko G, Ehrlich, Hartmut, Barrett, P. Noel, Kreil, Thomas R

“…Abstract Ross River Virus has caused reported outbreaks of epidemic polyarthritis, a chronic debilitating disease associated with significant long-term…”
Get full text

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity by Hessel, Annett, Schwendinger, Michael, Holzer, Georg W, Orlinger, Klaus K, Coulibaly, Sogue, Savidis-Dacho, Helga, Zips, Marie-Luise, Crowe, Brian A, Kreil, Thomas R, Ehrlich, Hartmut J, Barrett, P Noel, Falkner, Falko G

“…New highly pathogenic H5N1 influenza viruses are continuing to evolve with a potential threat for an influenza pandemic. So far, the H5N1 influenza viruses…”
Get full text

A Cell Culture—Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals by Ehrlich, Hartmut J., Singer, Julia, Berezuk, Gregory, Fritsch, Sandor, Aichinger, Gerald, Hart, Mary Kate, El-Amin, Wael, Portsmouth, Daniel, Kistner, Otfried, Barrett, P. Noel

“…Background. Current knowledge of the consistency of protection induced by seasonal influenza vaccines over the duration of a full influenza season is limited,…”
Get full text

Chikungunya virus and the safety of plasma products by Leydold, Sandra M., Farcet, Maria R., Kindermann, Johanna, Modrof, Jens, Pölsler, Gerhard, Berting, Andreas, Howard, M. Keith, Barrett, P. Noel, Kreil, Thomas R.

“…BACKGROUND: Chikungunya virus (CHIKV) outbreaks were previously restricted to parts of Africa, Indian Ocean Islands, South Asia, and Southeast Asia. In 2007,…”
Get full text

Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model by Schwendinger, Michael G, O'Rourke, Maria, Traweger, Andreas, Savidis-Dacho, Helga, Pilz, Andreas, Portsmouth, Daniel, Livey, Ian, Barrett, P Noel, Crowe, Brian A

“…For clinical development of a novel multivalent OspA vaccine against Lyme borreliosis, serological assays are required which can be used to establish immune…”
Get full text

Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study by Rutsaert, Sofie, Steens, Jean-Marc, Gineste, Paul, Cole, Basiel, Kint, Sam, Barrett, P Noel, Tazi, Jamal, Scherrer, Didier, Ehrlich, Hartmut J, Vandekerckhove, Linos

“…Objectives: To assess the safety and tolerability as well as antiretroviral impact of ABX464, an oral investigational drug with a novel mechanism of HIV-1…”
Get full text

Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial by Aichinger, Gerald, Ehrlich, Hartmut J, Aaskov, John G, Fritsch, Sandor, Thomasser, Christiane, Draxler, Wolfgang, Wolzt, Michael, Müller, Markus, Pinl, Fritz, Van Damme, Pierre, Hens, Annick, Levy, Jack, Portsmouth, Daniel, Holzer, Georg, Kistner, Otfried, Kreil, Thomas R, Barrett, P. Noel

“…Highlights ► First report of a clinical trial of a vaccine to prevent Ross River virus disease. ► Vero cell culture-derived inactivated RRV vaccine is safe and…”
Get full text